[go: up one dir, main page]

MX2015008588A - Composiciones y metodos para la transfeccion de polinucleótidos. - Google Patents

Composiciones y metodos para la transfeccion de polinucleótidos.

Info

Publication number
MX2015008588A
MX2015008588A MX2015008588A MX2015008588A MX2015008588A MX 2015008588 A MX2015008588 A MX 2015008588A MX 2015008588 A MX2015008588 A MX 2015008588A MX 2015008588 A MX2015008588 A MX 2015008588A MX 2015008588 A MX2015008588 A MX 2015008588A
Authority
MX
Mexico
Prior art keywords
compositions
methods
polynucleotide transfection
polynucleotide
transfection
Prior art date
Application number
MX2015008588A
Other languages
English (en)
Inventor
Kirk Hou
Samuel A Wickline
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of MX2015008588A publication Critical patent/MX2015008588A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica que comprende un complejo de péptido-polinucleótido y los métodos de uso de esta.
MX2015008588A 2013-01-03 2014-01-03 Composiciones y metodos para la transfeccion de polinucleótidos. MX2015008588A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361748615P 2013-01-03 2013-01-03
US201361869634P 2013-08-23 2013-08-23
US201361873187P 2013-09-03 2013-09-03
PCT/US2014/010212 WO2014107596A1 (en) 2013-01-03 2014-01-03 Compositions and methods for polynucleotide transfection

Publications (1)

Publication Number Publication Date
MX2015008588A true MX2015008588A (es) 2016-01-12

Family

ID=51062478

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015008588A MX2015008588A (es) 2013-01-03 2014-01-03 Composiciones y metodos para la transfeccion de polinucleótidos.

Country Status (10)

Country Link
US (1) US9987371B2 (es)
EP (1) EP2941273B1 (es)
JP (3) JP2016505620A (es)
KR (1) KR20150103239A (es)
AU (1) AU2014204012B2 (es)
CA (1) CA2896834C (es)
ES (1) ES2693518T3 (es)
IL (1) IL239680B (es)
MX (1) MX2015008588A (es)
WO (1) WO2014107596A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2941273B1 (en) 2013-01-03 2018-08-22 Washington University Compositions and methods for polynucleotide transfection
CA2989200A1 (en) * 2015-07-02 2017-01-05 Washington University Peptide-polynucleotide complex for polynucleotide transfection
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
GB201704128D0 (en) * 2017-03-15 2017-04-26 Univ Swansea Method and apparatus for use in diagnosis and monitoring of colorectal cancer
US11529388B2 (en) 2019-05-10 2022-12-20 University Of South Florida Peptide-polynucleotide-hyaluronic acid nanoparticles and methods for polynucleotide transfection
KR102604882B1 (ko) * 2021-07-01 2023-11-21 인천대학교 산학협력단 신규 특이적 항암 및 항염증 siRNA 및 이의 용도
CN120769911A (zh) 2023-02-22 2025-10-10 艾尔塔米拉治疗公司 用于治疗疾病的抑制kras的组合物和方法
WO2025229137A1 (en) * 2024-04-30 2025-11-06 Altamira Therapeutics Ag Compositions for p65 inhibition and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098032B2 (en) 2001-01-02 2006-08-29 Mirus Bio Corporation Compositions and methods for drug delivery using pH sensitive molecules
US7446099B2 (en) * 2004-02-27 2008-11-04 Nitto Denko Corporation Compositions and methods for biodegradable polymer-peptide mediated transfection
WO2007069090A2 (en) * 2005-12-06 2007-06-21 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
US20070275923A1 (en) * 2006-05-25 2007-11-29 Nastech Pharmaceutical Company Inc. CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
US7795380B2 (en) 2006-06-02 2010-09-14 University Of Iowa Research Foundation Compositions and methods for nucleic acid delivery
WO2009151788A2 (en) * 2008-04-22 2009-12-17 The Washington University Universal anchor peptide for nanoparticles
WO2011020188A1 (en) * 2009-08-21 2011-02-24 University Of Waterloo Peptide sequences and peptide-mediated sirna delivery
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
EP2941273B1 (en) 2013-01-03 2018-08-22 Washington University Compositions and methods for polynucleotide transfection
CA2989200A1 (en) * 2015-07-02 2017-01-05 Washington University Peptide-polynucleotide complex for polynucleotide transfection

Also Published As

Publication number Publication date
EP2941273B1 (en) 2018-08-22
WO2014107596A1 (en) 2014-07-10
HK1217432A1 (en) 2017-01-13
WO2014107596A8 (en) 2015-02-05
AU2014204012B2 (en) 2018-03-29
EP2941273A1 (en) 2015-11-11
EP2941273A4 (en) 2017-01-04
ES2693518T3 (es) 2018-12-12
IL239680A0 (en) 2015-08-31
JP2021100933A (ja) 2021-07-08
CA2896834A1 (en) 2014-07-10
CA2896834C (en) 2019-02-26
AU2014204012A1 (en) 2015-07-23
JP2016505620A (ja) 2016-02-25
IL239680B (en) 2020-03-31
KR20150103239A (ko) 2015-09-09
JP2019131561A (ja) 2019-08-08
US20150314013A1 (en) 2015-11-05
US9987371B2 (en) 2018-06-05
JP7227640B2 (ja) 2023-02-22

Similar Documents

Publication Publication Date Title
IL288961A (en) Pharmaceutical preparations
PL3104718T3 (pl) Kompozycja żelowa zawierająca tytoń
GEP20217239B (en) Pharmaceutical composition
SMT201900684T1 (it) Composizione farmaceutica combinata
PL2943181T3 (pl) Kompozycje farmaceutyczne
PL3043778T3 (pl) Kompozycje farmaceutyczne zawierające refametinib
GB201409471D0 (en) Pharmaceutical composition
ZA201408333B (en) Pharmaceutical compositions
MX2015008588A (es) Composiciones y metodos para la transfeccion de polinucleótidos.
ZA201403276B (en) Low dose pharmaceutical composition
SG11201605366QA (en) Pharmaceutical composition containing pyridylaminoacetic acidcompound
GB201409488D0 (en) Pharmaceutical composition
GB201409485D0 (en) Pharmaceutical composition
GEP20217240B (en) Pharmaceutical composition
SG11201601477VA (en) Pharmaceutical composition
SG11201509017VA (en) Compositions and methods for nutrient delivery
ZA201502073B (en) Pharmaceutical composition
PT3089740T (pt) Composição farmacêutica
HUP1300496A2 (hu) Stabil kombinációs gyógyszerkészítmény
IL244365A0 (en) pharmaceutical preparation
ZA201500995B (en) Low dose pharmaceutical composition
SG10201504332VA (en) Pharmaceutical Composition
AP2015008890A0 (en) Pharmaceutical compositions
ZA201800354B (en) Fuel composition
GB201304699D0 (en) Pharmaceutical compositions